ArticleJTO clinical and research reports2026
FDG-PET/CT SUVmax Predicts Recurrence Risk of Resected Pleuropulmonary Solitary Fibrous Tumors.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Risk stratification of pleuropulmonary solitary fibrous tumors (SFTs) is based on post-resection histopathologic scoring systems. We queried whether preoperative 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) maximum standardized uptake values (SUVmax) had prognostic value for recurrence or metastasis. Methods: Retrospective review of patients who underwent FDG-PET/CT before resection of SFT between January 2002 and June 2023. Independent review of slides by a pulmonary pathologist and radiologist review of FDG-PET/CT were performed. Statistical analyses included nonparametric tests for correlations, receiver-operating characteristic (ROC) curves, and Kaplan-Meier analysis. Results: There were 34 patients with a preoperative FDG-PET/CT before SFT resection. Median tumor SUVmax was 2.3 (range: 0.9-38.7). Recurrence occurred in five patients (14.7%) (three local, two metastatic). Tumor SUVmax was associated with tumor size ( Conclusions: Tumor metabolic activity on FDG-PET/CT is predictive of SFT recurrence. Preoperative SUVmax correlates with known histopathologic high-risk features and validated risk scores. Preoperative FDG-PET/CT should be performed before SFT resection to assist in prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.